Promising new MS Drug and Model
Submitted by enhydra lutris on Tue, 04/04/2017 - 12:26pmOn March 28th, the FDA approved ocrelizumab (brand name Ocrevus) to treat both relapsing-remitting MS and primary progressive MS. This is the first time a therapy has been available for severe forms of the Multiple Sclerosis. This follows upon the heels of spectacular results from a pair of major international clinical trials led by Stephen Hauser, M.D., of U.S.Can Francisco, confirming that ocrelizumab can block the inflammation that drives the disease.